Overview

The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

The investigators research the early improvement of fluid retention and mid-term prognosis through the administration of tolvaptan for the patient with tricuspid regurgitation and right heart failure after left heart valves replacement.

Phase:

Phase 4

Details

Lead Sponsor:

Shanghai Chest Hospital

Treatments:

Tolvaptan
Torsemide